Today: 1 July 2026
Browse Category

NYSE:RCUS 14 December 2025 - 8 January 2026

Arcus Biosciences (RCUS) Stock News, Forecasts and Analyst Targets — Dec. 14, 2025 Update

Arcus Biosciences (RCUS) Stock News, Forecasts and Analyst Targets — Dec. 14, 2025 Update

Arcus Biosciences, Inc. is ending the weekend under a bright—and volatile—spotlight after a major clinical-program reset triggered a sharp Friday selloff. As of Sunday, December 14, 2025, the last reported close was $21.53, down 14.36% from the prior session, reflecting investor repricing after Arcus and partner Gilead halted a pivotal upper-GI cancer study. StockAnalysis What comes next for Arcus Biosciences stock now hinges less on TIGIT in gastric cancer and more on whether casdatifan can become a durable “anchor” asset in kidney cancer—and whether Arcus’ early move into inflammation and immunology can add long-dated upside without burning credibility along the way. Reuters+1
14 December 2025
···

Stock Market Today

  • US Futures Dip as Oil Drops, Investors Weigh Inflation Signals
    July 1, 2026, 5:49 AM EDT. US stock futures slipped early Wednesday, with E-mini S&P 500 and Micro E-mini Nasdaq-100 contracts both down as trading opened to mixed macro news. The Strategic Petroleum Reserve is now at its lowest since 1983 after a big release aimed at lowering fuel prices, temporarily easing inflation on consumers. Oil retreated, while eurozone inflation stuck close to the 2% mark, leaving questions about just how much cheaper energy will affect banks, utilities, and real estate stocks. Sandisk jumped almost 11% on a price target bump, Credo Technology climbed on new index inclusions, and Bloom Energy advanced with more funding. Traders watched for fresh inflation data, oil supply numbers, and China's manufacturing reports as they tried to gauge how stable markets are with rate hikes still in focus.
Go toTop